LNTH Lantheus Holdings, Inc.

CIK 0001521036 31 ready 8-Ks latest May 7, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 31

Latest filing May 7, 2026, 7:59 PM ET

Top materiality 0.90

Event mix earnings ×11 · leadership ×8 · other_material ×5

Sentiment 13 pos · 1 neg · 17 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for LNTH

Highest-materiality recent filing

Lantheus to Acquire Life Molecular Imaging for $350M Upfront with Potential $400M Earnout

January 13, 2025, 6:59 PM ET M&A materiality 0.90 positive item 1.01 item 7.01 item 9.01

Upfront cash payment of $350M for Life Molecular Imaging, with up to $400M in potential earnout and milestone payments.
Acquisition adds Neuraceq (florbetaben F18), an FDA-approved PET imaging agent for Alzheimer's disease diagnosis.

Read filing →

May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Lantheus Q1 revenue $377.3M (+1.2% YoY); GAAP EPS $1.80, adjusted EPS $1.46

Worldwide revenue $377.3M (+1.2%); GAAP diluted EPS $1.80 (+76.5%), adjusted diluted EPS $1.46 (-4.6%).
May 1, 2026, 7:59 PM ET other material materiality 0.60 neutral item 3.03 item 5.03 item 5.02 item 5.07 item 9.01 ◈ Governance Changes

Lantheus shareholders approve board declassification and amended equity plan with 2M additional shares

Certificate of Amendment filed to declassify Board of Directors over three years; removal with/without cause after declassification.
February 26, 2026, 6:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01

Lantheus Q4 revenue $406.8M, adj EPS $1.67; narrows focus to PET radiodiagnostics

Worldwide revenue $406.8M (+4% YoY); FY2025 revenue $1.54B; GAAP diluted EPS $0.82 Q4, $3.41 FY.
November 12, 2025, 6:59 PM ET leadership materiality 0.65 neutral item 5.02

Lantheus CEO Brian Markison to retire Dec 31, 2025; consulting deal through Mar 31, 2026

CEO Brian Markison retiring effective Dec 31, 2025; enters consulting agreement from Jan 1 to Mar 31, 2026.
November 6, 2025, 6:59 PM ET earnings materiality 0.85 neutral item 2.02 item 5.02 item 7.01 item 9.01

Lantheus Q3 revenue $384M (+1.4% YoY), adj. EPS $1.27; CEO Markison to retire, Heino interim CEO

GAAP net income $27.8M ($0.41 fully diluted EPS); adjusted EPS $1.27, down 25.3% YoY.
August 11, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02

Lantheus CCO Amanda Morgan takes personal leave effective Aug. 8, 2025

Chief Commercial Officer Amanda Morgan on personal leave starting August 8, 2025.
August 6, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 8.01 item 9.01

Lantheus Q2 rev $378M, adj EPS $1.57; cuts FY25 guidance; FDA NDA acceptance; $400M buyback

Q2 revenue $378.0M (-4.1% YoY); GAAP EPS $1.12; adjusted EPS $1.57.
July 22, 2025, 7:59 PM ET M&A materiality 0.75 positive item 2.01 item 7.01 item 9.01 ◈ M&A Transactions

Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D

Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.
May 7, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Lantheus Q1 adj EPS $1.53 (-9.5% YoY); cuts FY25 adj EPS guidance to $6.60-$6.70 from $7.00-$7.20

Q1 revenue $372.8M (+0.8% YoY); GAAP EPS $1.02 vs $1.87; adj EPS $1.53 vs $1.69.
May 5, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.03 item 5.07 item 9.01

Lantheus stockholders elect four Class I directors and approve board declassification proposal

All four nominees elected: Mary Anne Heino (54.3M for), Dr. Gérard Ber (57.2M for), Julie Eastland (56.1M for), Samuel Leno (41.5M for).
April 1, 2025, 7:59 PM ET M&A materiality 0.75 positive item 2.01 item 7.01 item 9.01 ◈ M&A Transactions

Lantheus closes $275M acquisition of Evergreen Theragnostics; adds OCTEVY and CDMO capabilities

Closed acquisition of Evergreen Theragnostics for $275M cash upfront ($250M + $25M milestone achieved pre-close).
February 26, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Lantheus Q4 revenue $391M (+10.5%); GAAP EPS $(0.17), adj. EPS $1.59; FY25 guide $1.55B-$1.61B

Q4 revenue $391.1M (+10.5% YoY); PYLARIFY $266M (+15.7%), DEFINITY $86.2M (+17.9%).
January 30, 2025, 6:59 PM ET leadership materiality 0.45 positive item 5.02 item 9.01 ◈ executive_change

Lantheus appoints Dr. Phuong Khanh Morrow to board, effective Feb 1, 2025

Dr. Phuong Khanh Morrow appointed independent director effective Feb 1, 2025; board expands to 11.
January 28, 2025, 6:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.02 item 7.01 item 9.01

Lantheus to acquire Evergreen Theragnostics for $250M upfront plus up to $752.5M in milestones

Upfront cash consideration $250M; potential milestone payments up to $752.5M based on OCTEVY and pipeline products.
January 13, 2025, 6:59 PM ET M&A materiality 0.90 positive item 1.01 item 7.01 item 9.01

Lantheus to Acquire Life Molecular Imaging for $350M Upfront with Potential $400M Earnout

Upfront cash payment of $350M for Life Molecular Imaging, with up to $400M in potential earnout and milestone payments.
December 23, 2024, 6:59 PM ET debt materiality 0.72 positive item 1.01 item 2.03 item 9.01

Lantheus expands revolving credit facility to $750M, extends maturity to Dec 2029

Revolving line increased from $350M to $750M; can request another $350M.
December 19, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 7.01

Lantheus CMO Jeff Humphrey to depart Jan 3, 2025; search underway for replacement

Jeff Humphrey, MD, resigns as Chief Medical Officer; last day January 3, 2025.
November 20, 2024, 6:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Lantheus authorizes $250M share repurchase program over next 12 months

Board authorized up to $250M in common stock repurchases within one year.
November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Lantheus Q3 revenue up 18.4% to $378.7M; adjusted EPS $1.70 beats prior year

GAAP net income $131.1M ($1.79 diluted EPS) vs $132.0M ($1.88) in Q3 2023.
September 25, 2024, 7:59 PM ET other material materiality 0.65 neutral item 7.01

Lantheus to release SPLASH trial data in Oct 2024 after 75% OS events reached

Expects to release Phase 3 SPLASH data in October 2024 for 177Lu-PNT2002 in PSMA-expressing mCRPC.
September 5, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01 ◈ executive_change

Lantheus appoints Julie Eastland to Board of Directors, effective Sept 3, 2024

Board size increased to ten directors; Eastland is a Class I director and Audit Committee member.
July 31, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Lantheus Q2 revenue up 22.5% to $394.1M, adjusted EPS $1.80; lowers FY 2024 adjusted EPS guidance to $6.60-$6.70

Revenue $394.1M (+22.5% YoY), driven by PYLARIFY sales $273.3M (+29.8%) and DEFINITY $78.1M (+10.7%).
June 27, 2024, 7:59 PM ET M&A materiality 0.68 positive item 7.01 item 9.01

Lantheus acquires global rights to Life Molecular's GRPR-targeting radiotheranostic pair for $35M upfront

Upfront payment $35M plus regulatory milestone payments and royalties.
June 24, 2024, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 ◈ executive_change ×2

Lantheus appoints Kimberly Brown as Chief Accounting Officer effective July 1, 2024

Brown joins from Repligen (VP Controller); Andrea Sabens transitions to new role as of August 1.
May 15, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 9.01 ◈ executive_change

Lantheus appoints new CMO and CSO; Humphrey and Provost roles change May 28

Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer, both effective May 28, 2024.
May 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Lantheus Q1 revenue $370M (+23% YoY), EPS $1.87; raises FY2024 guidance

Q1 revenue $370M (+23% YoY); PYLARIFY sales $258.9M (+32.4%), DEFINITY $76.6M (+11.2%)
April 29, 2024, 7:59 PM ET other material materiality 0.30 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

Lantheus shareholders approve 4M share equity plan increase; re-elect directors

Stockholders approved amendment increasing share reserve under 2015 Equity Incentive Plan by 4,000,000 to 14,930,277.
February 22, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Lantheus Q4 2023 rev $354M (+34.5%), adj EPS $1.75; FY2024 guidance raised

Q4 2023 revenue $354M (+34.5% YoY), including $15M RELISTOR milestone; FY2023 revenue $1.3B (+38.6% YoY).
January 26, 2024, 6:59 PM ET litigation materiality 0.60 neutral item 7.01

Lantheus confirms patent infringement lawsuit by Novartis over generic Lutetium Lu 177 Dotatate ANDA

Lawsuit filed by Advanced Accelerator Applications (Novartis entities) in U.S. District Court for Delaware against Lantheus and its subsidiary.
January 23, 2024, 6:59 PM ET leadership materiality 0.80 positive item 5.02 item 9.01 ◈ executive_change ×5

Lantheus CEO Heino retires March 1; Markison named CEO; FY23 revenue $1.295-1.297B, up 38-39%

Mary Anne Heino to retire as CEO effective March 1, 2024; becomes Chair of the Board.
January 9, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Lantheus pre-announces FY2023 revenue ~$1.296B, beating guidance; PYLARIFY up 62%

Worldwide revenue expected $1.295-1.297B, up 38-39% YoY, above prior guidance of $1.255-1.270B.